Literature DB >> 34235727

Actions of glucagon-like peptide-1 receptor ligands in the gut.

Jens Juul Holst1, Daniel Bjørklund Andersen1, Kaare Villum Grunddal1.   

Abstract

The incretin hormone glucagon-like peptide-1 (GLP-1) is inactivated by the enzyme dipeptidyl peptidase-4 even before it leaves the gut, but it seems to act predominantly via activation of intestinal sensory neurons expressing GLP-1 receptors. Thus, activation of vagal afferents is probably responsible for its effects on appetite and food intake, gastrointestinal secretion and motility, and pancreatic endocrine secretion. However, GLP-1 receptors are widely expressed in the gastrointestinal (GI) tract, including epithelial cells in the stomach, and the Brunner glands, in endocrine cells of the gut epithelium, and on mucosal lymphocytes. In this way, GLP-1 may have important local actions of epithelial protection and endocrine signalling and may interact with the immune system. We review the formation and release of GLP-1 from the endocrine L cells and its fate after release and describe the localization of its receptor throughout the GI tract and discuss its direct or indirect actions in the GI tract. LINKED ARTICLES: This article is part of a themed issue on GLP1 receptor ligands (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.4/issuetoc.
© 2021 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34235727      PMCID: PMC8820219          DOI: 10.1111/bph.15611

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  133 in total

1.  Identification of cells with pancreatic-type and gut-type glucagon immunoreactivity in the human colon.

Authors:  J B Knudsen; J J Holst; S Asnaes; A Johansen
Journal:  Acta Pathol Microbiol Scand A       Date:  1975-11

2.  Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.

Authors:  J J Holst; C F Deacon
Journal:  Diabetologia       Date:  2005-03-10       Impact factor: 10.122

3.  Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2).

Authors:  C Orskov; J J Holst
Journal:  Scand J Clin Lab Invest       Date:  1987-04       Impact factor: 1.713

4.  Relationship of glicentin to proglucagon and glucagon in the porcine pancreas.

Authors:  A J Moody; J J Holst; L Thim; S L Jensen
Journal:  Nature       Date:  1981-02-05       Impact factor: 49.962

5.  Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.

Authors:  A Mari; W M Sallas; Y L He; C Watson; M Ligueros-Saylan; B E Dunning; C F Deacon; J J Holst; J E Foley
Journal:  J Clin Endocrinol Metab       Date:  2005-05-10       Impact factor: 5.958

6.  Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat.

Authors:  V Bucinskaite; T Tolessa; J Pedersen; B Rydqvist; L Zerihun; J J Holst; P M Hellström
Journal:  Neurogastroenterol Motil       Date:  2009-05-13       Impact factor: 3.598

7.  Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man.

Authors:  A Wettergren; H Petersen; C Orskov; J Christiansen; S P Sheikh; J J Holst
Journal:  Scand J Gastroenterol       Date:  1994-06       Impact factor: 2.423

Review 8.  Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2.

Authors:  Daniel J Drucker; Bernardo Yusta
Journal:  Annu Rev Physiol       Date:  2013-10-25       Impact factor: 19.318

Review 9.  Actions of glucagon-like peptide-1 receptor ligands in the gut.

Authors:  Jens Juul Holst; Daniel Bjørklund Andersen; Kaare Villum Grunddal
Journal:  Br J Pharmacol       Date:  2021-08-04       Impact factor: 8.739

10.  Single cell transcriptomic profiling of large intestinal enteroendocrine cells in mice - Identification of selective stimuli for insulin-like peptide-5 and glucagon-like peptide-1 co-expressing cells.

Authors:  Lawrence J Billing; Pierre Larraufie; Jo Lewis; Andrew Leiter; Joyce Li; Brian Lam; Giles Sh Yeo; Deborah A Goldspink; Richard G Kay; Fiona M Gribble; Frank Reimann
Journal:  Mol Metab       Date:  2019-09-07       Impact factor: 7.422

View more
  6 in total

1.  Functional human gastrointestinal organoids can be engineered from three primary germ layers derived separately from pluripotent stem cells.

Authors:  Alexandra K Eicher; Daniel O Kechele; Nambirajan Sundaram; H Matthew Berns; Holly M Poling; Lauren E Haines; J Guillermo Sanchez; Keishi Kishimoto; Mansa Krishnamurthy; Lu Han; Aaron M Zorn; Michael A Helmrath; James M Wells
Journal:  Cell Stem Cell       Date:  2021-12-01       Impact factor: 24.633

2.  An inter-organ neural circuit for appetite suppression.

Authors:  Tong Zhang; Matthew H Perkins; Hao Chang; Wenfei Han; Ivan E de Araujo
Journal:  Cell       Date:  2022-06-02       Impact factor: 66.850

Review 3.  GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?

Authors:  Maurício Reis Pedrosa; Denise Reis Franco; Hannah Waisberg Gieremek; Camila Maia Vidal; Fernanda Bronzeri; Alexia de Cassia Rocha; Luis Gabriel de Carvalho Cara; Sofia Lenzi Fogo; Freddy Goldberg Eliaschewitz
Journal:  Curr Atheroscler Rep       Date:  2022-08-31       Impact factor: 5.967

Review 4.  Discovery of the GI Effects of GLP-1: An Historical Perspective.

Authors:  Jens Juul Holst
Journal:  Dig Dis Sci       Date:  2022-05-30       Impact factor: 3.487

5.  New developments in the prospects for GLP-1 therapy.

Authors:  Stefan Trapp; S Clare Stanford
Journal:  Br J Pharmacol       Date:  2022-02       Impact factor: 9.473

Review 6.  Actions of glucagon-like peptide-1 receptor ligands in the gut.

Authors:  Jens Juul Holst; Daniel Bjørklund Andersen; Kaare Villum Grunddal
Journal:  Br J Pharmacol       Date:  2021-08-04       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.